Stonehouse Jon P's Form 4 filing
Biocryst Pharmaceuticals Inc (BCRX) · filed Dec 2, 2022
- Accession no.
- 0001127602-22-026832
- Filed
- Dec 2, 2022
- Trade date
- Dec 1-2, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.85M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stonehouse Jon PCIK 0001385496 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2022 | Common Stock | MOption exerciseAcquired | +214,917 | $1.42 | +$305,182.14 | 1,116,747 | Direct | |
| Dec 1, 2022 | Common Stock | SSaleDisposed | −214,917 | $13.00 | −$2,793,921 | 901,830 | Direct | |
| Dec 2, 2022 | Common Stock | MOption exerciseAcquired | +82,656 | $1.42 | +$117,371.52 | 984,486 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −82,656 | $12.80 | −$1,057,996.8 | 901,830 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2022 | Common Stock | MOption exerciseDisposed | −214,917 | $0.00 | $0 | 82,656 | Direct | |
| Dec 2, 2022 | Common Stock | MOption exerciseDisposed | −82,656 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.